Micron sets the oncology as the one of the prioritized field and supports the image assessment for the anti cancer drug clinical trials. We are experienced in each phases (phase I to phase III), PMS (Post Marketing Surveillance) and doctor-initiated clinical trials. From this experience, we have acquired a wide range of expertise. We will be flexible in our support and reading of system development in ophan cancer clinical trials.
|Malignant lymphoma||CT/CT, PET||Cheson(1999, 2007)|
|Malignant pleural mesothelioma||CT, PET||mRECIST / volumetric analysis|
|Leukemia||CT||NCI working group guideline||Korea|
|Lung cancer||CT||RECIST1.0, RECIST1.1||Korea, Taiwan|
|Bladder cancer||CT||WHO, RECIST1.1, irRC|
|Esophageal cancer||CT||RECIST1.1, irRC|
|Soft tissue tumor||CT||RECIST1.1|
|Prostate cancer||CT, Bone Scan||RECIST1.1, PCWG2, PCWG3||China, Korea, Taiwan, Hongkong|
|Liver cancer||CT||RECIST1.1||China, Korea, Taiwan, Singapore|
|Gallbladder cancer/ Cholangiocarcinoma||CT||RECIST1.1|
|Brain tumor /Head and neck cancer||CT, PET, MRI||RANO|
We cover international standards and papers and expirenced major evaluation criteria for each disease area such as RECIST 1.1, Modified RECIST 1.1, Cheson 1999, Cheson 2007, RANO, irRECIST, PCWG2, PCWG3.
Our Training Environment
Compared to the clinical trials of other disease areas, it is said that oncology studies are very complicated. Full knowledge of RECIST, other criterias, and various guidelines are required to handle the oncology studies. At Micron, we conduct both introductory and appropriate follow-up training to our employees who join our oncology team. Additionally, oncology team members participate in various cancer academic conferences such as those by the Japanese Society of Medical Oncology and the Japan Society of Clinical Oncology. We also participate in seminars to glean the latest information in oncology research. From these trainings and conferences, we strive to provide high-quality service and data for various oncology studies.